Categories: News

Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021.

A webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations.   A replay of the webcast will be archived for 90 days following the conference.  

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.

CONTACT: Investor & Media Contact

Steve Kunszabo        
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com

Staff

Recent Posts

CardioComm Solutions Announces Intention to Settle Outstanding Debt with Issuance of Shares

Toronto, Ontario--(Newsfile Corp. - July 25, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or…

3 minutes ago

PDS Health and DEXIS Successfully Bring AI-Powered and 3D Imaging to More Than 1,000 Dental Practices Nationwide

Strategic collaboration brings advanced AI and CBCT imaging to more than 1,000 dental practices, enhancing…

7 hours ago

Exactech Reaches Consensual Agreement with Unsecured Creditors Committee, Completes Court Filing of Amended Plan

Plan Confirmation and Sale Approval Court Date Expected in Early September GAINESVILLE, Fla., July 24,…

7 hours ago

Tali AI Joins QHR’s Marketplace to Bring AI Scribing to Accuro®EMR Users

TORONTO, July 24, 2025 /CNW/ - Tali AI, the leading Canadian healthtech company focused on reducing…

7 hours ago

Diabetes Diagnostics Enters New Era: Kalorama Highlights Digital Shift and Global Surge in HbA1c Testing

ARLINGTON, Va., July 24, 2025 /PRNewswire/ -- The global fight against diabetes is accelerating—and diagnostic innovation…

7 hours ago